Effectiveness of a Spectacle Lens with a Specific Asymmetric Myopic Peripheral Defocus: 12-Month Results in a Spanish Population

Background: Different designs of ophthalmic lenses have been studied to control the progression of myopia in children. This study aims to evaluate the short-term efficacy of a new design of ophthalmic lens with asymmetric myopic peripheral defocus (MPDL) on myopia progression in children compared to...

ver descrição completa

Detalhes bibliográficos
Autores: Sánchez Tena, Miguel Ángel, Cleva, Jose Miguel, Villa Collar, César, Álvarez, Marta, Ruiz Pomeda, Alicia, Martínez Pérez, Clara, Andreu Vázquez, Cristina, Chamorro, Eva, Álvarez Peregrina, Cristina
Tipo de documento: artigo
Data de publicação:2024
País:España
Recursos:Universidad Complutense de Madrid (UCM)
Repositório:Docta Complutense
Idioma:inglês
OAI Identifier:oai:docta.ucm.es:20.500.14352/104200
Acesso em linha:https://hdl.handle.net/20.500.14352/104200
Access Level:Acceso aberto
Palavra-chave:617.7-089.243
617.753.2
681.735
children
efficacy
myopia
myopic peripheral defocus lenses
Óptica y optometría
Óptica oftálmica
Pediatría
2209.15 Optometría
3311.09 Lentes
2209.24 Física de la Visión
Descrição
Resumo:Background: Different designs of ophthalmic lenses have been studied to control the progression of myopia in children. This study aims to evaluate the short-term efficacy of a new design of ophthalmic lens with asymmetric myopic peripheral defocus (MPDL) on myopia progression in children compared to a control group wearing a single-vision lens (SVL). Methods: Children aged 5 to 12 with myopia up to -0.50 D, astigmatism and anisometropia under 1.50 D, and corrected visual acuity over 20/20 were randomized to either the study group (MPDL) or control group (SVL). The myopia progression was evaluated by measuring axial length (AL) growth (IOL Master; Zeiss) over a period of one year. Results: Ninety-two subjects were recruited. Forty-six children were randomly assigned to the control group, and 46 to the study group. In total, 83 children completed the clinical trial, with a mean age of 10.81 [9.53-11.92] years, among which 59.04% were female. After one year of treatment, there was less AL elongation in the study group compared to the control group (0.16 ± 0.16 mm vs. 0.24 ± 0.16 mm, p = 0.034). Conclusions: The MPDL significantly reduced the absolute growth of AL by 39% (p = 0.014) and relative growth of AL by 37.3% (p = 0.012) after 12 months in comparison to the control group in a Spanish population.